[go: up one dir, main page]

WO2018038292A1 - Composition pharmaceutique contenant comme principe actif un extrait de cinnamomum camphora et destinée à la prévention et au traitement de maladies neurologiques - Google Patents

Composition pharmaceutique contenant comme principe actif un extrait de cinnamomum camphora et destinée à la prévention et au traitement de maladies neurologiques Download PDF

Info

Publication number
WO2018038292A1
WO2018038292A1 PCT/KR2016/009447 KR2016009447W WO2018038292A1 WO 2018038292 A1 WO2018038292 A1 WO 2018038292A1 KR 2016009447 W KR2016009447 W KR 2016009447W WO 2018038292 A1 WO2018038292 A1 WO 2018038292A1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
prevention
extract
camphor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2016/009447
Other languages
English (en)
Korean (ko)
Inventor
조성훈
이화영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyung Hee University
Original Assignee
Kyung Hee University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyung Hee University filed Critical Kyung Hee University
Priority to PCT/KR2016/009447 priority Critical patent/WO2018038292A1/fr
Publication of WO2018038292A1 publication Critical patent/WO2018038292A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras

Definitions

  • the present invention is a camphor tree ( Cinnamomum Camphora ) relates to a pharmaceutical composition for the prevention and treatment of diseases of the nervous system containing the extract as an active ingredient.
  • dementia As we enter an aging society, there is an increasing interest in aging, as well as related neurological diseases such as diseases, strokes and Alzheimer's dementia.
  • dementia is one of the most widespread cell damage disorders. It is accompanied by degenerative mental disorders, especially memory disorders and loss of judgment. Types of dementia include vascular dementia (20-30%) due to narrowing or occlusion of the blood vessels, Alzheimer's dementia (50%), which is known to be caused by accumulation of beta amyloid protein in the brain, and a combination of these two causes. It can be broadly divided into mixed dementia (15-20%).
  • Alzheimer's dementia The most common type of dementia among patients is Alzheimer's dementia, and a recent study reports that by 2050, 1 in 85 people will have the disease, 43% of whom require intensive care (Prabhulkar S, Piatyszek R, et al. J Neurochem., 2012, 122, 374-381).
  • Alzheimer's dementia is largely classified into hereditary Alzheimer's disease and sporadic Alzheimer's disease.
  • Hereditary Alzheimer's disease accounts for about 5 to 10% of all Alzheimer's dementia patients and affects presenilin 1, amyloid precursor protein, and presenilin 2, which are known as causative genes. Mutations result in 100% Alzheimer's dementia.
  • Sporadic Alzheimer's disease accounts for the majority of Alzheimer's dementia patients and is a risk factor that increases the chances of developing Alzheimer's disease when mutations in apolipoprotein E or Alpha-2 macroglobulin occur. To date, the exact cause of the disease is unknown.
  • Alzheimer's dementia The pathological characteristics of Alzheimer's dementia include senile plaques that accumulate outside the neurons, neurofibrilary tangles that look like tangled threads within the neuronal cell bodies, and neuronal loss. Etc. can be mentioned. This pathological feature is present in all cases of hereditary Alzheimer's disease and sporadic Alzheimer's disease, of which toxic proteins called aggregated amyloid beta peptides have been identified as a major component of senile plaques.
  • Amyloid beta peptides are insoluble peptides consisting of 40 to 42 amino acids resulting from abnormal cleavage of amyloid proproteins, and excessive accumulation of amyloid beta peptides is reported to be common in all cases of hereditary Alzheimer's disease and sporadic Alzheimer's disease. It is considered a major pathogenic material for Alzheimer's disease.
  • amyloid proproteins are abnormally cleaved by ⁇ -secretase and amyloid beta peptides are produced when mutations of the presenilin 1 and 2 genes occur.
  • Necrosis of cerebral neurons is caused by amyloid beta peptides, which is known to cause Alzheimer's disease.
  • Camphor tree Cinnamomum camphora ) was designated as Natural Monument No. 162 in Korea and grows in Seogwipo, Jeju Island.
  • Camphor is a plant belonging to the family Lauraceae, with a height of 20 m and a height of 2 m in diameter, free of pests and long life. Mainly dried branches are called camphor, which has been used for medicinal purposes.
  • Camphor an essential oil, is the main ingredient in camphor.
  • cineol, ⁇ -pinene, 1-camphene, ⁇ -limonene, and saprol (safrol) and ⁇ -camphorene are reported to be contained.
  • camphor is very valued and treated as a national monopoly like ginseng in our country.
  • Camphor tree has been used as a cancer drug in the private sector in Jeju Island, but there are few reports on the physiological activity of camphor tree components.
  • the present inventors tried to develop a treatment for Alzheimer's dementia using herbal medicine or natural products with few side effects, and confirmed that camphor extract showed the effect of improving spatial cognition and improving spatial learning and memory in Alzheimer's dementia animal model.
  • the invention has been completed.
  • An object of the present invention is a camphor tree ( Cinnamomum Camphora ) to provide a pharmaceutical composition for the prevention and treatment of neurological diseases containing the extract as an active ingredient.
  • the present invention is a camphor tree ( Cinnamomum Camphora ) provides a pharmaceutical composition for the prevention and treatment of diseases of the nervous system containing the extract as an active ingredient.
  • the present invention provides a health functional food for the prevention and improvement of neurological diseases containing camphor extract as an active ingredient.
  • Camphor tree of the present invention Cinnamomum camphora ) extract has no effect on motor function, improves instantaneous spatial cognition and mitigates learning and memory reduction, thereby making camphor extract useful for improving and treating Alzheimer's dementia. Can be used.
  • negative control group administered with distilled water after Alzheimer's dementia induction
  • EXP. 1 (200 mg / kg): group administered with 200 mg / kg camphor extract after Alzheimer's dementia induction; And
  • EXP. 2 (600 mg / kg): A group of 600 mg / kg camphor extract was administered after Alzheimer's dementia induction.
  • FIG. 2 is a diagram showing the measurement of the instantaneous spatial cognition of mice after administration of camphor extract:
  • negative control group administered with distilled water after Alzheimer's dementia induction
  • EXP. 1 (200 mg / kg): group administered with 200 mg / kg camphor extract after Alzheimer's dementia induction; And
  • EXP. 2 (600 mg / kg): A group of 600 mg / kg camphor extract was administered after Alzheimer's dementia induction.
  • FIG. 3 is a diagram showing the measurement of learning and memory of mice after administration of camphor extract:
  • negative control group administered with distilled water after Alzheimer's dementia induction
  • EXP. 1 (200 mg / kg): group administered with 200 mg / kg camphor extract after Alzheimer's dementia induction; And
  • EXP. 2 (600 mg / kg): A group of 600 mg / kg camphor extract was administered after Alzheimer's dementia induction.
  • the present invention is a camphor tree ( Cinnamomum Camphora ) provides a pharmaceutical composition for the prevention and treatment of diseases of the nervous system containing the extract as an active ingredient.
  • the camphor tree can be used without limitation, such as those grown or commercially available.
  • the camphor tree may be any one of vine stems, branches, roots, stems, leaves, petals and buds of the cognate plant, but is not limited thereto.
  • the camphor tree leaves or cognate plant Most preferably, the leaves of the plant are used.
  • the extraction solvent of camphor extract is preferably water, alcohol or a mixture thereof.
  • the alcohol is preferably C 1 to C 2 lower alcohol, it is preferable to use a lower alcohol or ethanol or methanol.
  • the extraction method it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but not always limited thereto.
  • the extraction solvent is preferably extracted by adding 1 to 10 times the amount of dried camphor, and more preferably by adding 4 to 6 times.
  • the extraction temperature is preferably 20 to 100 ° C, more preferably 20 to 40 ° C, and most preferably room temperature, but is not limited thereto.
  • the extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, most preferably 24 hours, but is not limited thereto.
  • the number of extraction is preferably 1 to 5 times, more preferably 3 to 4 repetitions, and most preferably 3 times, but is not limited thereto.
  • the vacuum concentrator is preferably used as a vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
  • the neurological disorders specifically include spinal cord injury, Parkinson's disease, stroke, amyotrophic spinal lateral sclerosis, motor neuron injury, peripheral nerve injury due to trauma, ischemic brain injury, neonatal hypoxic ischemic brain injury, cerebral palsy , Epilepsy, refractory epilepsy, Alzheimer's disease, congenital metabolic neurological disease and traumatic brain injury, and may be any one selected from the group consisting of spinal cord injury,
  • the present invention is not limited thereto and is applicable to all neurological diseases that may occur due to nerve damage.
  • the present inventors pulverized the dried camphor leaf to extract the hot water using water or a mixed solvent of water and alcohol and freeze-dried to obtain a powder X.
  • the obtained camphor extract was administered to Alzheimer's dementia-induced mice, and it was confirmed that there was no problem of motor function and no effect on walking activity (see FIG. 1).
  • administration of the camphor extract to the Alzheimer's dementia-induced mice to perform the Y-shaped maze type test, Morris water maze test it was confirmed that the instantaneous spatial cognition is improved (see Fig. 2), the learning and memory reduction is alleviated (Fig. 3). Therefore, the camphor extract of the present invention can be usefully used for improving and treating Alzheimer's dementia.
  • compositions of the present invention may further comprise a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable of the invention is meant to exhibit properties that are not toxic to cells or humans exposed to the composition.
  • Compositions comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations. When formulated, it may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. which are commonly used.
  • the carrier, excipient and diluent may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, Polyvinyl pyrrolidone, saline, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, dextrin, calcium carbonate, propylene glycol and liquid paraffin, but There is no limitation, and any conventional carrier, excipient or diluent can be used.
  • the components may be added independently or in combination to the camphor extract which is the active ingredient.
  • Solid preparations for oral administration may include tablet pills, powders, granules, capsules, and the like, and such solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose or lactose in one or more compounds. (lactose), gelatin can be prepared by mixing. In addition to the simple excipients, lubricants such as magnesium stearate, talc and the like can also be used.
  • Liquid preparations for oral administration include suspensions, solution solutions, emulsions, and syrups, and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have.
  • Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • a suppository base witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the pharmaceutical composition of the present invention is a group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories It can have any one formulation selected from.
  • the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount.
  • a pharmaceutically effective amount There is no particular restriction on the dosage, and it may vary depending on body absorption, weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion and severity of disease.
  • the pharmaceutical compositions of the present invention may be prepared in consideration of the effective amount range, and the unit dosage form formulated in this way may be formulated using a specialized dosage method according to the judgment of a professional who monitors or observes the administration of the drug as required and the needs of the individual. It can be used or administered several times at regular time intervals.
  • the pharmaceutical composition of the present invention may be administered based on the amount of camphor extract 0.5 to 5000 mg / kg, preferably 50 to 500 mg / kg, more preferably 50 mg / kg per day
  • the administration may be administered once a day, or may be divided several times.
  • the present invention is a camphor tree ( Cinnamomum camphora ) Provides a health functional food for the prevention and improvement of neurological diseases containing the extract as an active ingredient.
  • the camphor tree can be used without limitation, such as those grown or commercially available.
  • the camphor tree may be any one of vine stems, branches, roots, stems, leaves, petals and buds of the cognate plant, but is not limited thereto.
  • the camphor tree leaves or cognate plant Most preferably, the leaves of the plant are used.
  • the extraction solvent of camphor extract is preferably water, alcohol or a mixture thereof.
  • the alcohol is preferably C 1 to C 2 lower alcohol, it is preferable to use a lower alcohol or ethanol or methanol.
  • the extraction method it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but not always limited thereto.
  • the extraction solvent is preferably extracted by adding 1 to 10 times the amount of dried camphor, and more preferably by adding 4 to 6 times.
  • the extraction temperature is preferably 20 to 100 ° C, more preferably 20 to 40 ° C, and most preferably room temperature, but is not limited thereto.
  • the extraction time is preferably 10 to 48 hours, more preferably 15 to 30 hours, most preferably 24 hours, but is not limited thereto.
  • the number of extraction is preferably 1 to 5 times, more preferably 3 to 4 repetitions, and most preferably 3 times, but is not limited thereto.
  • the vacuum concentrator is preferably used as a vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • the drying is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but is not limited thereto.
  • the neurological disorders specifically include spinal cord injury, Parkinson's disease, stroke, amyotrophic spinal lateral sclerosis, motor neuron injury, peripheral nerve injury due to trauma, ischemic brain injury, neonatal hypoxic ischemic brain injury, cerebral palsy , Epilepsy, refractory epilepsy, Alzheimer's disease, congenital metabolic neurological disease, and traumatic brain injury may be one selected from the group consisting of, more specifically, spinal cord injury, but The present invention is not limited thereto and is applicable to all neurological diseases that may occur due to nerve damage.
  • the present inventors pulverized the dried camphor leaf to extract the hot water using water or a mixed solvent of water and alcohol and freeze-dried to obtain a powder X.
  • the obtained camphor extract was administered to Alzheimer's dementia-induced mice, and it was confirmed that there was no problem of motor function and no effect on walking activity (see FIG. 1).
  • administration of the camphor extract to the Alzheimer's dementia-induced mice to perform the Y-shaped maze type test, Morris water maze test it was confirmed that the instantaneous spatial cognition is improved (see Fig. 2), the learning and memory reduction is alleviated (Fig. 3). Therefore, the camphor extract of the present invention can be usefully used for improving and treating Alzheimer's dementia.
  • the health functional food of the present invention may contain various flavors or natural carbohydrates as additional ingredients.
  • the above-mentioned natural carbohydrates are sugars such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose and polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol.
  • sugars such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose and polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol.
  • natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin, aspartame, and the like can be used.
  • the ratio of the natural carbohydrate can be selected from 0.01 to 0.04 parts by weight, specifically about 0.02 to 0.03 parts by weight per
  • the health functional food of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage.
  • these components can be used independently or in combination.
  • the ratio of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health food of the present invention.
  • Cinnamomum harvested from Yeosu, Jeollanam-do camphora ) leaves were dried and used in the experiment.
  • 100 g of the pulverized camphor leaf was added to 1 L of distilled water, stirred, and then refluxed at a temperature of 90 to 95 ° C. for 3 hours. Thereafter, the filtrate was separated, and the extract was concentrated under reduced pressure at 55 to 65 ° C., and then freeze-dried to obtain a herbal composition powder ⁇ 21.2 g.
  • amyloid beta peptide peptide Amylodi beta1- 42
  • animal model 42 Amylodi beta1- infused mouse model
  • Alzheimer's dementia animal model was prepared by injecting amyloid beta peptides into / lateral and -1.75mm dorsal / ventral from Bregma).
  • the mouse was placed in a 50 ⁇ 50 ⁇ 50 cm white acrylic box and the behavior was measured for 10 minutes using a video tracking system (video tracking system, smart v2.5.21).
  • video tracking system video tracking system, smart v2.5.21.
  • the amount of walking activity used was measured.
  • the animal model administered with distilled water after inducing Alzheimer's disease did not show a significant difference compared to the animal model that did not induce Alzheimer's disease.
  • the camphor leaf extract does not affect the walking activity amount.
  • the instrument used for the Y-shaped maze test is composed of three arms, each branch is 42 cm long, 3 cm wide, 12 cm high, and the angle at which the three branches are folded is 120 °. to be.
  • All the experimental devices consisted of black polyvinyl plastic, and each branch was set to A, B, and C. The mouse was carefully placed on one branch and allowed to move freely for 8 minutes. Recorded. At this time, it was recognized as valid only when the tail was completely entered, and it was recorded even when the branch went back to the branch. In each case, three different branches (ABC, CAB, and BCA) were considered as actual alterations and given one point. Through this, the change behavioral force defined as going into all three in sequence was calculated, and was calculated by the following Equation 1.
  • mice were transferred to the behavior observation room and stabilized 1 hour before the start of the experiment.
  • Maze specifications are 90 cm in diameter, 32.5 cm in height, and the white platform is 5 cm in diameter.
  • the periphery of the underwater maze kept the space cues always constant, such as computer systems and video thermostats connected to video cameras. The maze was then filled with water and placed under 1 cm of water height so that the mouse could not see the platform.
  • the maze was divided into four quarters using four markers and divided into northeast (NE), northwest (NW), southeast (SE), and southwest (SW), and a platform was installed in one quadrant of the maze.
  • the Morris water maze test was run for six days, and on the first day each mouse was allowed to swim freely in the maze for one minute to adapt to the water. From day 2 to day 5, each mouse was allowed to swim in the maze for 1 minute at 10 minute intervals, four times a day. In the first four days of the 5th day from the second day, a single test method will not find a platform within 1 minute after finishing the experiment, or 10 seconds on the platform if the mouse is already in the labyrinth for 10 seconds.
  • the mouse was artificially placed on the platform for 10 seconds and the experiment was terminated, and the position of the platform was fixed at the same position.
  • the platform was removed from the labyrinth and the time the mouse stayed in the garden where the platform was located was measured.
  • the free swimming was performed for 60 seconds after the platform was removed and the time spent in the quadrant of the total time was measured by the Smart program. .
  • the control group was 67.97 ⁇ 3.14481%
  • the negative control group administered with amyloid beta peptides was 38.56 ⁇ 2.69489%
  • the positive control group administered with amyloid beta peptides and donepezil was 60.4986 ⁇ 4.35727. %, 59.5614 ⁇ 3.235% of Experimental Group 1 administered 200 mg / kg of amyloid beta peptides and camphor leaf extract and 53.4714 ⁇ 4.62295% of Experimental Group 2 administered 600 mg / kg of amyloid beta peptides and camphor leaf extract.
  • Table 1 administered 200 mg / kg of amyloid beta peptides and camphor leaf extract
  • Experimental Group 2 administered 600 mg / kg of amyloid beta peptides and camphor leaf extract.
  • camphor extract has an improvement and treatment effect of Alzheimer's dementia by confirming that camphor leaf extract can alleviate the decrease in learning and memory that can occur when Alzheimer's dementia is induced. .

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pharmaceutique contenant comme principe actif un extrait de Cinnamomum camphora et destinée à la prévention et au traitement de maladies neurologiques. Il a été confirmé que lorsque l'extrait de Cinnamomum camphora est préparé et injecté dans un modèle animal de la démence associée à la maladie d'Alzheimer, la perception spatiale instantanée du modèle animal est améliorée et le déclin de l'apprentissage et de la mémoire est atténué, confirmant ainsi que l'extrait de Cinnamomum camphora pourrait être utilisé efficacement pour soulager et traiter la démence associée à la maladie d'Alzheimer.
PCT/KR2016/009447 2016-08-25 2016-08-25 Composition pharmaceutique contenant comme principe actif un extrait de cinnamomum camphora et destinée à la prévention et au traitement de maladies neurologiques Ceased WO2018038292A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2016/009447 WO2018038292A1 (fr) 2016-08-25 2016-08-25 Composition pharmaceutique contenant comme principe actif un extrait de cinnamomum camphora et destinée à la prévention et au traitement de maladies neurologiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2016/009447 WO2018038292A1 (fr) 2016-08-25 2016-08-25 Composition pharmaceutique contenant comme principe actif un extrait de cinnamomum camphora et destinée à la prévention et au traitement de maladies neurologiques

Publications (1)

Publication Number Publication Date
WO2018038292A1 true WO2018038292A1 (fr) 2018-03-01

Family

ID=61244979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/009447 Ceased WO2018038292A1 (fr) 2016-08-25 2016-08-25 Composition pharmaceutique contenant comme principe actif un extrait de cinnamomum camphora et destinée à la prévention et au traitement de maladies neurologiques

Country Status (1)

Country Link
WO (1) WO2018038292A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022223814A1 (fr) * 2021-04-23 2022-10-27 Laboratoire Aroma Science Composition pharmaceutique et nutraceutique comprenant un mélange de plantes pour la prevention et le traitement de maladies neurodegeneratives

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050081631A (ko) * 2004-02-16 2005-08-19 대한민국 (소관: 제주대학교) 녹나무 추출물을 함유하는 염증성 질환의 예방 및 치료용조성물
KR20100058032A (ko) * 2008-11-24 2010-06-03 경희대학교 산학협력단 계피나무 추출물, 이의 분획물 또는 계피나무로부터 분리한트랜스―신남알데하이드를 유효성분으로 함유하는 파킨슨 질환 예방 및 치료용 조성물
WO2012091685A1 (fr) * 2010-12-30 2012-07-05 Anandechakunkorn Siridechpong Médicaments traditionnels modifiés à base d'herbes thaï
KR20140132482A (ko) * 2013-05-08 2014-11-18 한남대학교 산학협력단 녹나무 추출물을 유효성분으로 함유하는 암 예방 또는 개선용 식품 조성물 및 약학 조성물
CN105662036A (zh) * 2016-01-28 2016-06-15 上海安丁生物(汤阴)药业有限公司 三香红木枕

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050081631A (ko) * 2004-02-16 2005-08-19 대한민국 (소관: 제주대학교) 녹나무 추출물을 함유하는 염증성 질환의 예방 및 치료용조성물
KR20100058032A (ko) * 2008-11-24 2010-06-03 경희대학교 산학협력단 계피나무 추출물, 이의 분획물 또는 계피나무로부터 분리한트랜스―신남알데하이드를 유효성분으로 함유하는 파킨슨 질환 예방 및 치료용 조성물
WO2012091685A1 (fr) * 2010-12-30 2012-07-05 Anandechakunkorn Siridechpong Médicaments traditionnels modifiés à base d'herbes thaï
KR20140132482A (ko) * 2013-05-08 2014-11-18 한남대학교 산학협력단 녹나무 추출물을 유효성분으로 함유하는 암 예방 또는 개선용 식품 조성물 및 약학 조성물
CN105662036A (zh) * 2016-01-28 2016-06-15 上海安丁生物(汤阴)药业有限公司 三香红木枕

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022223814A1 (fr) * 2021-04-23 2022-10-27 Laboratoire Aroma Science Composition pharmaceutique et nutraceutique comprenant un mélange de plantes pour la prevention et le traitement de maladies neurodegeneratives
FR3122085A1 (fr) * 2021-04-23 2022-10-28 Laboratoire Aroma Science Compositions pharmaceutique et nutraceutique pour la prevention et le traitement de maladies neurodegeneratives

Similar Documents

Publication Publication Date Title
US20200397845A1 (en) Composition comprising the extract of herbs for preventing or treating neurodegenerative disorders
WO2010104309A9 (fr) Compositions pour prévenir ou améliorer des maladies gastro-intestinales
WO2010058926A2 (fr) Composition pharmaceutique contenant un extrait de gingembre ou du shogaol
WO2011059292A2 (fr) Concentré ou extrait de pousse d'aloès officinal favorisant fortement la croissance des cellules cutanées et présentant des effets anti-allergiques et antioxydants supérieurs
WO2018174453A1 (fr) Composition contenant un extrait de cirsium ja p onicum en tant que principe actif pour stimuler la mélanogenèse
WO2017213306A1 (fr) Composition pour l'amélioration de la mémoire comprenant un extrait de feuilles de petasites japonicus
WO2021215598A1 (fr) Composition pour la prévention ou le traitement de l'épilepsie et son procédé de préparation
WO2014025202A1 (fr) Composition pharmaceutique contenant un mélange d'extrait de zingiber officinale rosc et d'extrait de paeonia lactiflora pallas, destinée à prévenir ou à traiter les démences et les troubles cognitifs
WO2021080129A1 (fr) Composition pour renforcer la barrière cutanée et soulager la dermatite atopique, comprenant de l'hydrangénol ou de la phyllodulcine en tant que principe actif
WO2018038292A1 (fr) Composition pharmaceutique contenant comme principe actif un extrait de cinnamomum camphora et destinée à la prévention et au traitement de maladies neurologiques
WO2019124854A1 (fr) Composition pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant un extrait mixte ou une fraction de celui-ci
KR102437152B1 (ko) 로가닉산을 포함하는 인지장애 관련 질환의 예방 또는 치료용 약학 조성물
WO2018038293A1 (fr) Composition pharmaceutique contenant un extrait de sophora japonica l. en tant que principe actif pour la prévention et le traitement de troubles neurodégénératifs
WO2014171583A1 (fr) Composition pour prévenir ou traiter un accident vasculaire cérébral ou une maladie dégénérative du cerveau
KR102080684B1 (ko) 녹나무 추출물을 유효성분으로 함유하는 신경계 질환의 예방 및 치료용 약학적 조성물
US20160000849A1 (en) Composition for remedying or treating rheumatoid arthritis and osteoarthritis
WO2023054918A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du dysfonctionnement cognitif comprenant, comme principes actifs, des cellules souches à néprilysine surexprimée, leurs solutions de culture et les exosomes isolés à partir de celles-ci
CN101588810A (zh) 用于治疗和预防炎性疾病的包括络石藤和日本鹿蹄草提取物的组合物
WO2018230942A1 (fr) Composition contenant un extrait ou une fraction d'extrait de reynoutria japonica pour prévenir et traiter le syndrome de l'œil sec
WO2018008973A1 (fr) Composition comprenant un extrait de forsythiae fructus en tant que principe efficace pour prévenir, améliorer ou traiter la neuropathie périphérique
US20230263852A1 (en) Composition For Preventing Or Treating Neurodegenerative Diseases Containing Mixed Herbal Extract Of Genkwae Flos, Clematidis Radix, And Gastrodiae Rhizoma
WO2017111429A1 (fr) Composition pour le traitement du syndrome de sécheresse oculaire, contenant un extrait d'airelle noire en tant que substance active
KR20180108267A (ko) 홍화자 추출물을 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학 조성물
KR20020078850A (ko) 신경보호작용을 갖는 당귀추출물 및 이를 함유하는 약학적제제
KR20160124352A (ko) 녹나무 추출물을 유효성분으로 함유하는 신경계 질환의 예방 및 치료용 약학적 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16914271

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16914271

Country of ref document: EP

Kind code of ref document: A1